ArticleBiomaterials2013
Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 57 citations in OpenAlex.
- Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases.American journal of ophthalmology · 2025Review
- Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Poly(β-amino ester)s-based nanovehicles: Structural regulation and gene delivery.Molecular therapy. Nucleic acids · 2023Review
- A protocol to inject ocular drug implants into mouse eyes.STAR protocols · 2022Article
- An intravitreal implant injection method for sustained drug delivery into mouse eyes.Cell reports methods · 2021Article
- Enhancement of bioactivity, thermal stability and tumor retention by self-fused concatenation of green fluorescent protein.Biochemistry and biophysics reports · 2021Article
- Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy.Journal of nanobiotechnology · 2021Review
- Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.Acta biomaterialia · 2019Article
- Single-Emulsion P(HB-HV) Microsphere Preparation Tuned by Copolymer Molar Mass and Additive Interaction.ACS omega · 2019Article
- Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.Investigative ophthalmology & visual science · 2018Article
- Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery.Acta biomaterialia · 2018Article
- Functional intercalated nanocomposites with chitosan-glutathione-glycylsarcosine and layered double hydroxides for topical ocular drug delivery.International journal of nanomedicine · 2018Article
- Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers.Investigative ophthalmology & visual science · 2017Article
- Gene delivery nanoparticles to modulate angiogenesis.Advanced drug delivery reviews · 2017Review
- Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.Science translational medicine · 2017Article
- A Critical Analysis of the AvailableJournal of ophthalmology · 2017Review
- Reactive Center Loop (RCL) Peptides Derived from Serpins Display Independent Coagulation and Immune Modulating Activities.The Journal of biological chemistry · 2016Article
- Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.Investigative ophthalmology & visual science · 2016Article
- In vitro-in vivo correlation from lactide-co-glycolide polymeric dosage forms.Progress in biomaterials · 2014Article
- Inhibition of breast cancer growth and metastasis by a biomimetic peptide.Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Aberrant angiogenesis can cause or contribute to a number of diseases such as neovascular age-related macular degeneration (NVAMD). While current NVAMD treatments target angiogenesis, these treatments are not effective for all patients and also require frequent intravitreal injections. New agents and delivery systems to treat NVAMD could be beneficial to many patients. We have recently developed a serpin-derived peptide as an anti-angiogenic agent. Here, this peptide is investigated for activity in human retinal endothelial cells in vitro and for reducing angiogenesis in a laser-induced choroidal neovascularization mouse model of NVAMD in vivo. While frequent intravitreal injections can be tolerated clinically, reducing the number of injections can improve patient compliance, safety, and outcomes. To achieve this goal, and to maximize the in vivo activity of injected peptide, we have developed biodegradable polymers and controlled release particle formulations to extend anti-angiogenic therapy. To create these devices, the anionic peptides are first self-assembled into nanoparticles using a biodegradable cationic polymer and then as a second step, these nanoparticles are encapsulated into biodegradable poly(lactic-co-glycolic acid) (PLGA) microparticles. In situ, these particles show approximately zero-order, linear release of the anionic peptide over 200 days. These particles are made of safe, hydrolytically degradable polymers and have low endotoxin. Long-term in vivo experiments in the laser-induced neovascularization model for NVAMD show that these peptide-releasing particles decrease angiogenesis for at least fourteen weeks in vivo following a single particle dose and therefore are a promising treatment strategy for NVAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.